News

The U.S. Food and Drug Administration has approved Fycompa (perampanel) — alone or as an add-on — for the treatment of focal seizures, which affect only one part of the brain, with or without secondary generalized seizures, in children ages 4 and older. The approval includes Fycompa administered as a…

Stoke Therapeutics’ targeted-augmentation of nuclear gene output (TANGO) technology effectively increased the levels of the SCN1A gene and of its encoded protein in mice with Dravet syndrome. The company is currently conducting additional preclinical studies to evaluate the functional impact of this potential treatment strategy for Dravet syndrome. Isabel…

For the first time, positron emission tomography (PET) scans revealed a significant decrease in the amount of glucose uptake in the brains of children with Dravet syndrome. Interestingly, this reduction was more evident in older children. However, it is still unclear if the reduction in glucose uptake is a…

Supernus Pharmaceuticals now holds the worldwide rights — except in certain markets in Asia — to develop the investigational therapy BIS-001ER, renamed SPN-817, for Dravet syndrome, after a merger agreement to acquire Biscayne Neurotherapeutics, according to a press release. “We are excited to add…

More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…

Researchers found that patients with Dravet syndrome are at higher risk of suffering sudden unexpected death in epilepsy (SUDEP) due to genetic mutations in the SCN1A gene that predispose them to heart arrhythmias. University of Michigan Medical School investigators now plan to look at the potential use of already approved…

Vagus nerve stimulation (VNS) therapy can lead to more than $77,000 in cost savings over five years for patients with drug-resistant epilepsy (DRE), compared to anti-epileptic treatments, according to new research. The study, “Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy…

Zogenix’s lead investigational compound ZX008 provided significant and long-term seizure reduction in Dravet syndrome patients, according to new clinical trial data. The company also revealed data from multiple studies assessing the psychological and socioeconomic impact of epileptic encephalopathies, including Dravet syndrome, in the United States and Europe. These findings were presented in multiple studies during…

Early diagnosis followed by treatment with anti-epileptic medications reduced the frequency of seizures and behavioral problems in three children with both Dravet syndrome and autism spectrum disorder (ASD), a study reports. The study, “Epileptic Encephalopathy and Autism: A Complex Interplay,” was published in the Journal of Pediatric…

GW Pharmaceuticals has presented positive data on the safety and effectiveness of Epidiolex, recently approved by the U.S. Food and Drug Administration (FDA) to treat epileptic seizures in Dravet and Lennox-Gastaut syndromes, as well as the potential mechanisms behind its anti-epileptic properties. The data were presented at the 13th Annual…